RT Book, Section
A1 Flexner, Charles
A2 Brunton, Laurence L.
A2 Chabner, Bruce A.
A2 Knollmann, Björn C.
SR Print(0)
ID 1127871336
T1 Antiretroviral Agents and Treatment of HIV Infection
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071624428
LK accessanesthesiology.mhmedical.com/content.aspx?aid=1127871336
RD 2023/10/01
AB There  are  currently  several  million  people  taking  chronic  combination  antiretroviral  therapy  to  suppress  human  immunodeficiency  virus  (HIV)  infection,  including  >3  million  in  sub-Saharan  Africa  alone.  This  is  an  amazing  achievement  for  a  disease  that  was  uniformly  fatal  and  with  few  treatment  options  just  two  decades  ago.  Combination  antiretroviral  therapy  prolongs  life  and  prevents  progression  of  disease  caused  by  HIV.  The  pharmacotherapy  of  HIV  infection  is  a  rapidly  moving  field.  In  2009,  24  antiretroviral  drugs  were  available  in  the  U.S.  Three-drug  combinations  are  the  minimum  standard  of  care  for  this  infection,  so  current  agents  constitute  several  thousand  possible  regimens.  The  long-term  management  of  a  patient  on  antiretroviral  therapy  can  be  daunting,  even  for  experienced  healthcare  providers.  Knowing  the  essential  features  of  the  pathophysiology  of  this  disease  and  how  chemotherapeutic  agents  affect  the  virus  and  the  host  is  critical  in  developing  a  rational  approach  to  therapy.  Unique  features  of  this  drug  class  include  the  need  for  lifelong  administration  to  control  virus  replication  and  the  possibility  of  rapid  emergence  of  permanent  drug  resistance  if  these  agents  are  not  used  properly.